A Phase 1 interventional study of human insulin in Diabetes and Healthy, sponsored by Novo Nordisk A/S. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-27.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing Insulin, Regular, Human in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus.
Among the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, this one is the 26th largest by enrollment, is one of 5 that started in 2002, is one of 8 in phase 1, and was the 28th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus are open now, in 1 country. Recruiting first, the newest first:
Mannkind Corporation · Sites in United States
Ages 6–17
Columbia University · Sites in United States
Ages 18–65
By country, each count listing its studies:
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 50 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4 · Phase 3 18 · Phase 4 9
First in 1989; this study’s year is marked. 5 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 60 across the 41 interventional studies. Of the 38 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 41 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
642 studies in Diabetes Mellitus by Novo Nordisk A/S: 2 open now, 3 under way, 1 of them phase 3. Of 636 finished, 163 (26%) have results posted.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 404th largest by enrollment of the 494 interventional ones that give a count, is one of 33 that started in 2002, is one of 206 in phase 1, and was the 300th registered.
Novo Nordisk A/S’s Diabetes Mellitus studies by the year they started, since 1989.
1 of the studies testing Insulin, Regular, Human in Diabetes Mellitus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07224321Mannkind CorporationINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 642 in Diabetes Mellitus:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe. The aim of this trial is to show that the product of the new production process has a similar pharmacological profile to the traditional process used for the current commercial product Actrapid®.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: human insulin
Drug: human insulin
Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
AUC (area under the curve) 0-8h (human insulin)
Cmax (maximum plasma concentration)
Area under the curve (glucose infusion rate (GIR)), 0-8h
tmax (time to reach maximum)
t½ (terminal half-life)
GIR (glucose infusion rate) max
tGIR (glucose infusion rate) max
Area under the curve (C-peptide, 0-8h)
Physical examinations and vital signs
Ran from Oct 2002 to primary completion in Dec 2002, 2 months.
Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 2 months is below that.
Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human